Maryam B. Lustberg

Maryam B. Lustberg, MD, MPH is Chief of Breast Medical Oncology at Yale Cancer Center and Associate Professor of Medicine at Yale School of Medicine. She is an internationally recognized leader at the intersection of breast oncology and cardio-oncology, with particular focus on cardiovascular toxicities associated with CDK4/6 inhibitors, endocrine therapies, and novel breast cancer treatments including antibody-drug conjugates. Dr. Lustberg was among the first to systematically characterize the QTc prolongation associated with ribociclib and the cardiac monitoring requirements for CDK4/6 inhibitor-treated patients, work that shaped FDA labeling and clinical monitoring guidelines. She directs a dedicated cardio-oncology program and has led prospective studies examining cardiac biomarker changes, echocardiographic parameters, and patient-reported cardiovascular symptoms in women receiving long-term CDK4/6 inhibitor and endocrine therapy combinations. Dr. Lustberg has also been a champion for equity in breast cancer outcomes and toxicity management, studying how cardiovascular comorbidities interact with treatment tolerability across diverse populations. Prior to joining Yale, she was at The Ohio State University Comprehensive Cancer Center. She serves on the ASCO Survivorship Guideline Committee and the American Society for Preventive Cardiology, and has published more than 150 peer-reviewed articles.